BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 3167612)

  • 1. Treatment of metastatic breast cancer with AZQ: a phase II trial.
    Martino S; Ratanatharathorn V; Samal BA; Singhakowinta A; Haas C
    Cancer Invest; 1988; 6(3):289-91. PubMed ID: 3167612
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II clinical evaluation of AZQ in metastatic breast cancer.
    Yap HY; Bedikian AY; Schell FC; Blumenschein GR; Bodey GP
    Am J Clin Oncol; 1983 Feb; 6(1):31-3. PubMed ID: 6837505
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II clinical evaluation of AZQ in adenocarcinoma of the lung.
    Decker DA; Samson MK; Haas CD; Baker LH
    Am J Clin Oncol; 1984 Aug; 7(4):353-5. PubMed ID: 6741865
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II clinical evaluation of AZQ in renal cell carcinoma.
    Decker DA; Kish J; Al-Sarraf M; Goldfarb S
    Am J Clin Oncol; 1986 Apr; 9(2):126-8. PubMed ID: 3717078
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II study of aziridinylbenzoquinone (AZQ: NSC-182986) in the treatment of malignant gliomas recurrent after radiation. Preliminary report.
    Decker DA; Al Sarraf M; Kresge C; Austin D; Wilner HI
    J Neurooncol; 1985; 3(1):19-21. PubMed ID: 2987424
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I study of diaziquone.
    Frytak S; Eagan RT; Ames MM; Creagan ET; Nichols WC
    Cancer Treat Rep; 1984; 68(7-8):975-8. PubMed ID: 6744349
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aziridinylbenzoquinone (AZQ) in advanced breast cancer: a Cancer and Leukemia group B phase II trial.
    Budman DR; Forastiere A; Perloff M; Perry M; Aisner J; Weinberg V; Wood W
    Cancer Treat Rep; 1982 Oct; 66(10):1875-6. PubMed ID: 7127327
    [No Abstract]   [Full Text] [Related]  

  • 8. Phase I-II evaluation of intra-arterial diaziquone for recurrent malignant astrocytomas.
    Greenberg HS; Ensminger WD; Layton PB; Gebarski S; Meyer M; Chaffee B; Bender JF; Grillo-Lopez AJ
    Cancer Treat Rep; 1986 Mar; 70(3):353-7. PubMed ID: 3006913
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High dose AZQ in renal cancer. A Southwest Oncology Group phase II study.
    Stephens RL; Kirby R; Crawford ED; Bukowski R; Rivkin SE; O'Bryan RM
    Invest New Drugs; 1986; 4(1):57-9. PubMed ID: 3700042
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II trial of aziridinylbenzoquinone (AZQ) in patients with refractory small cell carcinoma of the lung.
    Fuks JZ; Aisner J; Van Echo DA; Levitt M; Ihde DC; Carney D; Wiernik PH
    Am J Clin Oncol; 1983 Apr; 6(2):171-3. PubMed ID: 6299094
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II study of an aziridinylbenzoquinone (AZQ) in disseminated malignant melanoma.
    Creagan ET; Schutt AJ; Ahmann DL; Green SJ
    Cancer Treat Rep; 1982 Dec; 66(12):2089-90. PubMed ID: 7139650
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II trial of aziridinylbenzoquinone (AZQ) in patients with refractory lymphoma.
    McLaughlin P; Cabanillas F; Bedikian AY; Bodey GP
    Cancer Treat Rep; 1983 May; 67(5):507-8. PubMed ID: 6850666
    [No Abstract]   [Full Text] [Related]  

  • 13. A phase I/II study of 24 hour intravenous AZQ in recurrent primary brain tumors.
    Chamberlain MC; Prados MD; Silver P; Levin VA
    J Neurooncol; 1988 Dec; 6(4):319-23. PubMed ID: 3221259
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II trial of diaziquone (AZQ) in advanced malignant melanoma.
    Høst H; Joss R; Pinedo H; Bruntsch U; Cavalli F; Renard G; van Glabbeke M; Rozencweig M
    Eur J Cancer Clin Oncol; 1983 Feb; 19(2):295-8. PubMed ID: 6681775
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I trial of 5-day continuous infusion aziridinylbenzoquinone (AZQ, diazaquone, NSC 182968).
    Sigman LM; Van Echo DA; Whitacre MY; Aisner J; Budman DA; Shulman P
    Am J Clin Oncol; 1986 Feb; 9(1):79-82. PubMed ID: 3953494
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II trial of diaziquone in patients with colon cancer.
    Neidhart JA; Erlichman C; Robert F; Velez-Garcia E; Bender JF; Grillo-López J
    Cancer Treat Rep; 1985 Feb; 69(2):215-7. PubMed ID: 3882229
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase II trial of 2,5,-diaziridinyl 3,6-bis (carboethoxy amino) 1,4-benzoquinone (AZQ, NSC 182986) in recurrent primary brain tumors.
    Feun LG; Yung WK; Leavens ME; Burgess MA; Obbens EA; Bedikian AY; Savaraj N; Stewart DJ; Benjamin RS; Fields WS
    J Neurooncol; 1984; 2(1):13-7. PubMed ID: 6088722
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preliminary communication--treatment of primary brain tumors recurrent after irradiation with aziridinylbenzoquinone (AZQ;NSC-182986).
    Eagan RT; Dinapoli RP; Hermann RC; Groover RV; Layton DD
    Am J Clin Oncol; 1983 Oct; 6(5):577-8. PubMed ID: 6613923
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comprehensive phase II evaluation of aziridinylbenzoquinone (AZQ, diaziquone) in recurrent human primary brain tumors.
    Eagan RT; Dinapoli RP; Cascino TL; Scheithauer B; O'Neill BP; O'Fallon JR
    J Neurooncol; 1987; 5(4):309-14. PubMed ID: 3440875
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II trial of aziridinylbenzoquinone (AZQ) in head and neck cancer.
    Forastiere AA; Crain SM; Callahan K; Van Echo D; Mattox D; Thant M; Von Hoff DD; Wiernik PH
    Cancer Treat Rep; 1982 Dec; 66(12):2097-8. PubMed ID: 6892491
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.